Pipeline & Medicines Explore the Science of Possibility View Vertex Research Giving BackLearn more about our STEM Program, Volunteer Efforts, Grants and Funding./giving-back Recent UpdatesFDA Approves SYMDEKOExpanded EU Approval for ORKAMBIKALYDECO Approved for Additional Mutations The Stories Behind Vertex: Science Third Positive Phase 2 Proof-of-Concept Study for VX-150 Further Validates the Potential Role of NaV1.8 Inhibition Science Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies Science European Commission grants Marketing Authorization for SYMKEVI® (tezacaftor/ivacaftor) Science Two Phase 3 Studies of the VX-659 Triple Combination Regimen Met Primary Endpoint of Improvement in Lung Function (ppFEV1) Science Our Commitment to Research & Development We Are Vertex Vertex’s Michael Parini Is Moved to Make a Difference Giving Back How Vertex’s New Discovery Camp Makes Summertime Learning Sizzle All in for CF 11-Year-Old with Cystic Fibrosis Joins Team Sports for the First Time Through the Vertex Team IMPACT CF Project × We Are Vertex Day of Service × All in for CF Amanda and Peter Krug Share Their Perspective on What It Takes To Care for Harry, Their 10-Year-Old Son Who Is Living with Cystic Fibrosis Explore More Stories @vertexpharma
Science Third Positive Phase 2 Proof-of-Concept Study for VX-150 Further Validates the Potential Role of NaV1.8 Inhibition
Science Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies
Science Two Phase 3 Studies of the VX-659 Triple Combination Regimen Met Primary Endpoint of Improvement in Lung Function (ppFEV1)
All in for CF 11-Year-Old with Cystic Fibrosis Joins Team Sports for the First Time Through the Vertex Team IMPACT CF Project
× All in for CF Amanda and Peter Krug Share Their Perspective on What It Takes To Care for Harry, Their 10-Year-Old Son Who Is Living with Cystic Fibrosis
